Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Data Analytics & AI · Trial registration and reporting

Mandatory Publication and Registration of Clinical Trials

Two separate obligations apply to clinical trials, and they are frequently conflated. Prospective registration is a condition that journals impose before they will consider a paper, whereas results reporting to a registry is a legal requirement in several jurisdictions, with a deadline measured from trial completion rather than from publication. Compliance with the second obligation is measurably poor, and the pattern of non-compliance raises concerns about where the incentives lie.

Pubrica AcademyWritten by the medical writing and biostatistics teams Reviewed byPubrica biostatistics team Published9 October 2026 Last checked9 October 2026 Reading time12 minutes Sources34 peer-reviewed

A trial registered after the first participant consents cannot regain eligibility for publication in an ICMJE journal, however diligent the subsequent conduct. A completed trial whose summary results are never posted may breach the law of the jurisdiction in which it was conducted, and the published audits indicate that such trials are in the majority. Under the US FDA Amendments Act, of 4,209 trials due to report results, 1,722 did so within the one-year deadline: 40.9%. A separate analysis of 13,327 highly likely applicable trials found 13.4% reporting within the mandated 12 months. Both figures merit careful consideration.

Learning objectives

  • The distinction between prospective registration, results reporting and journal publication, three obligations with three different triggers
  • The requirements of the ICMJE, including the 24-item minimum registration data set and the data-sharing requirements added in 2018 and 2019
  • The findings of compliance audits, and the reasons two credible analyses report very different percentages
  • The compliance of different sponsor types, with effect sizes
  • How to determine whether a trial is legally required to report results, and why a large share of sponsors make this determination incorrectly
  • The statements a manuscript should contain so that an editor can verify registration and reporting status in under a minute

Common misconceptions

  • “Registration is a formality you complete before submission.” ICMJE requires registration in a public registry at or before the first patient’s consent to enrolment, as a condition of publication. Registration after enrolment has begun constitutes retrospective registration; it is visible in the registry record and cannot be undone.
  • “Publishing the paper discharges the reporting obligation.” Publication does not discharge this obligation. Results reporting to a registry is a separate duty with its own deadline running from trial completion, and a trial can be published in a major journal and still be non-compliant.
  • “Most trials report their results on time.” Under FDAAA, 40.9% of 4,209 trials due to report did so within one year (95% CI 39.4% to 42.2%); 63.8% had submitted results at any time; the median time to submission was 424 days, which is 59 days beyond the requirement. A separate analysis of 13,327 trials found only 13.4% reporting within 12 months and 38.3% at any time.
  • “Industry sponsors are the problem.” The evidence on compliance indicates the opposite. Industry sponsorship was associated with an odds ratio of 3.08 (95% CI 2.52 to 3.77) for compliance versus non-industry sponsorship, and large sponsors against small ones with an odds ratio of 11.84 (95% CI 9.36 to 14.99). Trial volume and infrastructure predict compliance better than sector does.
  • “Every trial on a registry is required to report results.” This is not necessarily the case, and sponsors misjudge applicability in both directions. On sample review, 45% of industry trials assessed as highly likely applicable were not in fact required to report, against 6% of National Institutes of Health (NIH) trials and 9% of other government or academic trials.

Distinct triggers for registration, results reporting and publication

Distinguishing these three obligations is the central practical problem and therefore warrants explicit treatment.

Prospective registration is triggered by the first participant’s consent to enrolment. The ICMJE requires registration in a public registry at or before that point as a condition of considering the trial for publication 1. The sanction is editorial: a retrospectively registered trial may be declined, and the registration date is a public record that cannot be amended after the fact 1.

Results reporting is triggered by trial completion, and in several jurisdictions it is statutory rather than editorial. In the United States, the FDA Amendments Act requires submission of summary results to ClinicalTrials.gov within one year of the primary completion date for applicable clinical trials 8,14. The sanction is regulatory, and it is independent of whether a paper ever appears.

Publication has no external trigger and depends solely on the investigator’s decision to write. No jurisdiction compels journal publication, which is why the phrase “mandatory publication” is somewhat misleading: what is mandatory is registration before enrolment and reporting of results to the registry. Publication is the one element that cannot be required, which is precisely why the registry obligations exist.

Research teams frequently treat the first as administrative and the second as discharged by the third. Both errors are common, and both are externally visible. Our pages on ICMJE trial registration and the current ICMJE requirements set out the editorial side in detail.

Registration requirements of the ICMJE

There are four requirements, each with a specific trigger.

Timing. Registration is required at or before the first patient’s consent to enrolment: before the first consent, not merely before submission or before the first analysis.

Registry eligibility. Only registries that are WHO ICTRP primary registers and that carry the required characteristics are accepted 1,2. A record in an institutional database or a non-qualifying national registry does not satisfy the requirement, and this deficiency is costly to discover at submission.

Content. The minimum registration data set comprises 24 items 1. The outcome fields are the items most likely to cause later difficulty: a vaguely registered primary outcome gives readers no means of detecting outcome switching, whereas a precisely registered primary outcome binds the investigators to it. The latter is the purpose of registration.

Data sharing. A data-sharing statement has been required from 2018, and from 2019 a data-sharing plan has been required in the registration record itself 1. This requirement is the one most often missed by teams relying on an outdated understanding of the rules, because it affects the registry entry and not only the manuscript.

The protocol side runs in parallel. SPIRIT 2025 provides a 34-item checklist for reporting randomised trial protocols, focusing on content rather than format, and most of the registration data set can be transferred directly from a SPIRIT-complete protocol 20. If the protocol is complete, registration is a matter of transcription; if it is not, registration becomes a drafting exercise under time pressure, which is how vague outcome fields arise. See our SPIRIT checklist and protocol development pages.

Findings of compliance audits

The FDAAA analysis is the more straightforward of the two. Of 4,209 trials due to report results, 1,722 reported within the one-year deadline — 40.9%, with a 95% confidence interval of 39.4% to 42.2% 8. Results had been submitted at any time for 2,686 trials, or 63.8%. The median time to submission was 424 days, which is 59 days beyond the requirement.

The median is more informative than the headline figure. A median of 424 days indicates that the typical reporting trial missed the deadline by approximately two months, not by years. This pattern suggests a process problem rather than a refusal: sponsors who report mostly do so slightly late, whereas a separate group does not report at all. These two populations require different interventions, and a single compliance percentage conceals the distinction.

A second analysis covering 13,327 trials identified as highly likely applicable found a much lower rate: 13.4% reported summary results within the mandated 12 months and 38.3% at any time 14. Within that set, 77.4% were drug trials, 36.9% were phase 2, 23.4% phase 3, and 65.6% industry funded.

The two analyses differ by a factor of three on the headline rate, and the difference reflects definitions rather than a contradiction. The first counts trials established as due to report; the second counts trials assessed from registry fields as highly likely to be applicable, a larger and less precisely defined population 8,14. The appropriate figure to cite depends on the question being addressed, and citing either without stating how applicability was determined should be avoided.

Two compliance analyses, and why they disagree

MeasureTrials established as due to reportTrials assessed as highly likely applicable
Trials in the analysis4,20913,327
Reported within the deadline1,722 — 40.9% (95% CI 39.4% to 42.2%)13.4% within 12 months
Reported at any time2,686 — 63.8%38.3%
Median time to submission424 days, i.e. 59 days beyond the requirementNot reported in these terms
CompositionTrials due to report under FDAAA77.4% drug trials; 36.9% phase 2; 23.4% phase 3; 65.6% industry funded

The two analyses use different applicability definitions, which is the main source of the threefold difference in headline rate: the first counts trials established as due to report, the second counts trials assessed from registry fields as highly likely applicable. Quote either only with its definition attached.

40.9%of trials due to report did so within one year
63.8%had submitted results at any time
424days, median time to submission
59days beyond the requirement, at the median

Results reporting under the FDA Amendments Act, from an analysis of 4,209 trials due to report, of which 1,722 reported within the one-year deadline (95% CI 39.4% to 42.2%). The median overshoot of 59 days indicates a sequencing problem among reporting sponsors, distinct from the group that never reports at all.

Compliance by sponsor type

Compliance was strongly associated with sponsor type and with sponsor trial volume. Industry sponsorship carried an odds ratio of 3.08 for compliance against non-industry sponsorship, with a 95% confidence interval of 2.52 to 3.77 8. Large sponsors against small sponsors carried an odds ratio of 11.84, with a confidence interval of 9.36 to 14.99.

The second effect is nearly four times the first and may account for it. An odds ratio approaching 12 for large versus small sponsors is a finding about infrastructure rather than ethics: organisations that run many trials typically have staff whose responsibilities include registry submission, a calendar that tracks completion dates, and a standard operating procedure 8. Organisations running one or two trials typically rely on a principal investigator who also teaches, sees patients and supervises students, and for whom the registry deadline is one task among many, with no institutional reminder.

This has a direct implication for academic and small-sponsor trials, which account for most of the non-reporting. The remedy is administrative rather than motivational: the obligation should be assigned to a named role, with a calendar date, when the protocol is approved rather than when the trial closes. Our publication governance and publication planning work is designed largely to put that infrastructure in place.

What predicts compliance with results reporting

ComparisonOdds ratio for compliance95% confidence interval
Industry versus non-industry sponsor3.082.52 to 3.77
Large versus small sponsor, by trial volume11.849.36 to 14.99

From the FDAAA compliance analysis of 4,209 trials due to report. The volume effect is nearly four times the sector effect, which points to infrastructure rather than intent as the operative variable.

Errors in determining applicability

A further complication undermines much of the analysis that publicly ranks sponsors, and sponsors misjudge it in both directions. On sample review of trials assessed as highly likely applicable from their registry fields, the proportion found not to be required to report differed sharply by funder: 45% of industry trials, 6% of NIH trials, and 9% of other government or academic trials 14.

An error rate of 45% is substantial and has two implications. First, published compliance rankings that treat registry-derived applicability as ground truth will substantially overstate industry non-compliance 14. Second, a sponsor cannot determine its own obligation from the registry record alone, which, because the obligation is statutory, constitutes a governance risk rather than a technicality.

The appropriate response is to make the applicability determination explicitly, record it with its reasoning and date, and revisit it if the trial changes. A determination of “not applicable” that exists only as an unrecorded assumption is indistinguishable, externally and in an audit, from non-compliance.

Trials assessed as highly likely applicable that turned out not to be required to report

FunderShare not actually required, on sample review
Industry45%
NIH6%
Other government or academic9%

Sample review within the analysis of 13,327 trials identified as highly likely applicable. The disparity means that registry-derived applicability is a poor proxy for legal obligation, particularly for industry trials, and that compliance rankings built on it will misrepresent the relative performance of funders.

Scientific consequences of unreported trials

The ethical argument is familiar: participants consented on the understanding that the trial would contribute to knowledge, and an unreported trial breaches that understanding 2. The scientific argument is more specific and merits statement because it bears directly on ongoing research.

Every systematic review and meta-analysis draws on the published and registered record. If trials are missing from it non-randomly, as the compliance pattern suggests (small and academic sponsors being least likely to report), then the evidence base is a biased sample of the evidence 8. The direction of the bias cannot be determined from within the evidence base. A reviewer who searches registries as well as journals, and who reports how many registered trials had no retrievable results, is taking the only step that makes the gap visible.

There is also a cost of duplication. An unreported trial of an intervention invites repetition, in which a second set of participants is consented to answer a question that has already been answered but not reported. Our pages on the systematic review process and PRISMA reporting cover how to search and report that gap; duplicate publication covers the opposite failure.

Limits of journal enforcement

The influence of journals is strong at one point and absent at all others. At submission, an editor can require a registration number, check the registration date against the stated enrolment start, compare the registered primary outcome against the reported one, and require a data-sharing statement. Many do, and this is why the registration requirement changed behaviour where voluntary appeals had not.

Journals cannot, however, compel submission. A sponsor who decides not to write up a trial is entirely outside the editorial system, and no journal policy applies to that sponsor. This asymmetry is the reason results reporting to registries was made statutory: it is the only obligation that applies to a trial that nobody intends to publish, which is disproportionately a trial with an unwelcome result.

One further limitation should be noted. A journal can verify that a trial was registered and that its primary outcome matches; it cannot verify that the analysis conducted matched the analysis planned, because the registry record does not contain the analysis plan at that level of detail. That gap is addressed, if at all, by protocol and analysis-plan publication; see our analysis plan work and the CONSORT 2025 reporting requirements.

A workflow for maintaining compliance

Five steps are recommended, each placed at the point in the trial at which it is least costly.

At protocol approval. Write the registration record from the SPIRIT-complete protocol, with the primary outcome stated to the same precision as in the protocol, including the measurement instrument, the timepoint and the metric. Include the data-sharing plan, required in the registration record since 2019.

Before the first consent. Confirm the record is live and the registry is a WHO ICTRP primary register. This is the one deadline that cannot be repaired later.

At the same moment. Make the applicability determination for statutory results reporting, record the reasoning, and put the reporting deadline — one year from primary completion in the US — into a calendar owned by a named role rather than by the trial.

At any protocol amendment. Update the registry record, and update it visibly: an amended outcome with a dated registry history is a documented change, while an amended outcome that appears only in the manuscript is outcome switching.

At primary completion. Submit summary results whether or not a paper is in preparation, without waiting for the paper. The median reporting trial missed the deadline by 59 days, and almost all of that delay reflects a sequencing choice rather than an obstacle 8.

The registration and reporting statement in a manuscript (dates below are illustrative)

Unverifiable in one line

The trial was registered with ClinicalTrials.gov. Ethical approval was obtained from the institutional review board and all participants provided written informed consent. Data are available from the corresponding author on reasonable request.

No registration date. An editor cannot determine whether registration was prospective, which is the central concern of the ICMJE requirement.

No enrolment start date to compare it against. Even with a registration date, prospectivity is unverifiable without the date of first consent.

No link between the registered and the reported primary outcome. Outcome switching is concealed at this point, and the statement provides no means of verification.

Nothing about statutory results reporting. Publication does not discharge it, and the manuscript gives a reader no way to know whether it was done.

“Available on reasonable request” is not a data-sharing plan. A data-sharing statement has been required since 2018 and a plan in the registration record since 2019; this satisfies neither in substance.

No protocol or analysis plan. Consequently, the registered outcome can at best be checked, and the planned analysis cannot be checked at all.

Verifiable in one minute

The trial was registered prospectively at ClinicalTrials.gov on 14 February 2022, before the first participant consented on 3 March 2022 (registration number and accession details in the title page). The registered primary outcome — change in the six-minute walk distance from baseline to week 24, measured by the standardised protocol in Appendix 2 — is the primary outcome reported here; the registry history records one amendment, dated 11 August 2022, which added a secondary outcome and did not alter the primary. Summary results were submitted to the registry on 19 January 2025, within one year of the primary completion date of 28 February 2024. The full protocol and statistical analysis plan, both finalised before the first participant was enrolled, are provided as Supplementary Files 1 and 2, and the data-sharing plan registered with the trial record states that de-identified individual participant data will be available through the named repository from the date of publication, under the access conditions described there.

Both dates are present, so prospective registration is verifiable rather than asserted.

The registered and reported primary outcomes are shown to be the same object, measured the same way at the same timepoint.

The registry amendment history is disclosed with a date, which converts a change into a documented one rather than a discrepancy.

Statutory results submission is stated with its date and measured against the primary completion date, so the legal obligation is visibly discharged.

The data-sharing plan is specific about repository, availability date and access conditions, which is what the requirement asks for.

Protocol and analysis plan are supplied and dated relative to enrolment, which is the only way a reader can assess the analysis as well as the outcome.

Every claim in the second version can be checked against public records in approximately one minute, which corresponds to the time an editor is likely to spend on it. The first version requires the reader to accept every claim on trust, and the audit data indicate that such trust is poorly founded in this area.

Key points

Key points

Registration, results reporting and publication are three obligations with three different triggers. Prospective registration is triggered by the first participant’s consent and is a condition of publication in ICMJE journals, which accept only WHO ICTRP primary registers, require a 24-item minimum data set, and have required a data-sharing statement since 2018 and a data-sharing plan in the registration record since 2019. Statutory results reporting is triggered by primary completion and is not discharged by publishing a paper: under FDAAA, 40.9% of 4,209 trials due to report did so within the year, 63.8% ever did, and the median submission came 424 days after completion, 59 days late. Publication itself cannot be mandated, which is why registry reporting had to be. Compliance is associated with infrastructure rather than sector: the odds ratio for large versus small sponsors was 11.84, against 3.08 for industry versus non-industry. Applicability should be determined explicitly, because on sample review 45% of industry trials assessed as highly likely applicable were not in fact required to report.

Application to your study

Application to your study

  1. The registry record should be written from the protocol, not from memory. SPIRIT 2025 provides a 34-item checklist for reporting randomised trial protocols, and a SPIRIT-complete protocol contains almost all of the information that the 24-item registration data set requires.
  2. The trial should be registered before the first consent, and both dates should be recorded. This is the only deadline in the process that cannot be remedied afterwards.
  3. The registry should be confirmed as a WHO ICTRP primary register. An institutional or non-qualifying national record does not satisfy the ICMJE requirement, and discovering this at submission is costly.
  4. The primary outcome should be specified to the level of instrument, timepoint and metric. A precisely registered outcome is what makes outcome switching detectable, which is the purpose of registration.
  5. The applicability determination for results reporting should be made and recorded. The determination should be recorded with its reasoning and date at protocol approval. An unwritten assumption is indistinguishable from non-compliance in an audit.
  6. The reporting deadline should be assigned to a named person. The deadline of one year from primary completion should be owned by a role rather than by the trial. The volume effect on compliance suggests that this is what distinguishes compliant from non-compliant sponsors.
  7. Summary results should be submitted without waiting for the paper. The median late reporter was 59 days over the deadline, which reflects a sequencing decision more than an obstacle.
  8. The registry should be updated at every amendment. A dated registry history makes a changed outcome a documented change, whereas an unrecorded change becomes a discrepancy that a reviewer is likely to identify.

Frequently asked questions

At or before the first patient’s consent to enrolment. That is the ICMJE condition for considering a trial for publication, and it is a strict boundary: registration one day after the first consent is retrospective registration, the dates are public, and no subsequent diligence changes them. The registry must be a WHO ICTRP primary register that carries the required characteristics, so an institutional database or a non-qualifying national registry does not qualify. The minimum registration data set comprises 24 items, and since 2019 a data-sharing plan has been required in the registration record itself, in addition to the data-sharing statement required in manuscripts from 2018.

No. They are separate obligations with separate triggers and separate sanctions. Journal publication is an editorial process initiated by the investigator; statutory results reporting is a legal duty triggered by the primary completion date, requiring submission of summary results to the registry within a defined period — one year under the US FDA Amendments Act. A trial can appear in a major journal and still be non-compliant with the reporting requirement, and conversely a trial that never produces a paper still owes its registry results. In practice, the two should be decoupled: registry results should be submitted according to the statutory deadline, and the manuscript should follow its own timeline.

It depends on how applicability is defined, and the two principal analyses differ by roughly a factor of three for that reason. Of 4,209 trials established as due to report under FDAAA, 1,722 — 40.9%, with a 95% confidence interval of 39.4% to 42.2% — reported within one year, 63.8% reported at any time, and the median submission came 424 days after completion, 59 days beyond the requirement. A broader analysis of 13,327 trials assessed from registry fields as highly likely applicable found 13.4% reporting within 12 months and 38.3% at any time. Both are valid findings about different populations; citing either without its definition is a source of misinformation.

On this evidence, yes, although the mechanism is probably not the one commonly assumed. Industry sponsorship was associated with an odds ratio of 3.08 for compliance (95% CI 2.52 to 3.77) against non-industry sponsorship. However, the much stronger predictor was sponsor trial volume, with large versus small sponsors at an odds ratio of 11.84 (95% CI 9.36 to 14.99), nearly four times the sector effect and large enough to explain it. This pattern points to infrastructure: organisations running many trials have staff whose responsibilities include registry submission and a calendar that tracks completion dates, whereas organisations running one or two trials do not.

The determination should be made deliberately and recorded in writing, because the registry record is not a reliable guide. On sample review of trials assessed from registry fields as highly likely applicable, 45% of industry trials were found not to be required to report, against 6% of NIH trials and 9% of other government or academic trials. That error rate is large enough to invalidate registry-derived compliance rankings and, more importantly for sponsors, to make self-assessment from the registry entry unsafe. The determination should be made at protocol approval against the actual statutory criteria for the relevant jurisdiction, with the reasoning and the date recorded, and revisited if the trial design or the regulatory status of the product changes.

Retrospective registration should be disclosed and explained, and authors should expect it to count against them at some journals. It cannot be remedied, since the registration date is a fixed public record, but concealing it is worse than disclosing it: editors check, and a mismatch between the stated enrolment start and the registration date found by a reviewer is a far more serious problem than a declared one. The defensible approach is to state both dates explicitly in the manuscript, state the reason for the delay clearly, and provide the protocol and analysis plan with their own dates so that a reader can assess whether the outcomes and analysis were specified before results were available. Some journals will still decline the manuscript; others will consider it with the disclosure.

These are precisely the trials whose absence causes the most harm. Every systematic review and meta-analysis is built on the retrievable record, so if trials are missing from it non-randomly, as the compliance pattern indicates (small and non-industry sponsors being least likely to report), then the synthesised evidence is a biased sample, and the direction of the bias cannot be determined from within the review. There is also an argument grounded in the interests of participants, who consented on the understanding that the trial would contribute to knowledge. Furthermore, an unreported trial invites duplication, in which a second group of participants is consented to answer a question that has already been answered.

No, and this is the structural gap that registry reporting exists to close. A journal’s leverage applies only at submission, where an editor can demand a registration number, check the registration date against the enrolment start, compare the registered primary outcome with the reported one, and require a data-sharing statement. A sponsor who never submits is outside that system, and no editorial policy applies; this is disproportionately the case for trials whose results were commercially or academically unwelcome. Statutory results reporting is the only obligation that binds a trial nobody intends to publish, which is why the compliance figures for it matter more than any journal policy.

References

  1. International Committee of Medical Journal Editors. Clinical Trials (Section L, Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals). ICMJE. read 9 October 2026. icmje.org
  2. World Health Organization, International Clinical Trials Registry Platform. Trial registration. World Health Organization. read 9 October 2026. who.int
  3. de Viron S, Trotta L, Steijn W, Young S, Buyse M. Does Central Statistical Monitoring Improve Data Quality? An Analysis of 1,111 Sites in 159 Clinical Trials. Therapeutic Innovation & Regulatory Science. 2024;58(3):483-494. doi:10.1007/s43441-024-00613-w read 9 October 2026. doi.org/10.1007/s43441-024-00613-w
  4. de Viron S, Trotta L, Steijn W, Young S, Buyse M. Does Central Monitoring Lead to Higher Quality? An Analysis of Key Risk Indicator Outcomes. Therapeutic Innovation & Regulatory Science. 2022;57(2):295-303. doi:10.1007/s43441-022-00470-5 read 9 October 2026. doi.org/10.1007/s43441-022-00470-5
  5. Zeng L, Brignardello-Petersen R, Hultcrantz M, Mustafa RA, Murad MH, Iorio A, et al. GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. Journal of Clinical Epidemiology. 2022;150:216-224. doi:10.1016/j.jclinepi.2022.07.014 read 9 October 2026. doi.org/10.1016/j.jclinepi.2022.07.014
  6. Schunemann HJ, Neumann I, Hultcrantz M, Brignardello-Petersen R, Zeng L, Murad MH, et al. GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions. Journal of Clinical Epidemiology. 2022;150:225-242. doi:10.1016/j.jclinepi.2022.07.015 read 9 October 2026. doi.org/10.1016/j.jclinepi.2022.07.015
  7. Cragg WJ, Hurley C, Yorke-Edwards V, Stenning SP. Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: A scoping review. Clinical Trials. 2021;18(2):245-259. doi:10.1177/1740774520976561 read 9 October 2026. doi.org/10.1177/1740774520976561
  8. DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. The Lancet. 2020;395(10221):361-369. doi:10.1016/S0140-6736(19)33220-9 read 9 October 2026. doi.org/10.1016/S0140-6736(19)33220-9
  9. Stenning SP, Cragg WJ, Joffe N, Diaz-Montana C, Choudhury R, Sydes MR, et al. Triggered or routine site monitoring visits for randomised controlled trials: results of TEMPER, a prospective, matched-pair study. Clinical Trials. 2018;15:600-609. read 9 October 2026. journals.sagepub.com
  10. von Niederhausern B, Orleth A, Schadelin S, Rawi N, Velkopolszky M, Becherer C, et al. Generating evidence on a risk-based monitoring approach in the academic setting - lessons learned. BMC Medical Research Methodology. 2017;17(1):26. doi:10.1186/s12874-017-0308-6 read 9 October 2026. doi.org/10.1186/s12874-017-0308-6
  11. Brosteanu O, Schwarz G, Houben P, Paulus U, Strenge-Hesse A, Zettelmeyer U, et al. Risk-adapted monitoring is not inferior to extensive on-site monitoring: results of the ADAMON cluster-randomised study. Clinical Trials. 2017;14:584-596. read 9 October 2026. journals.sagepub.com
  12. Buyse M, Squifflet P, Coart E, Quinaux E, Punt CJA, Saad ED. The impact of data errors on the outcome of randomized clinical trials. Clinical Trials. 2017;14(5):499-506. read 9 October 2026. journals.sagepub.com
  13. Olsen R, Bihlet AR, Kalakou F, Andersen JR. The impact of clinical trial monitoring approaches on data integrity and cost - a review of current literature. European Journal of Clinical Pharmacology. 2016;72(4):399-412. read 9 October 2026. journals.sagepub.com
  14. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. New England Journal of Medicine. 2015;372(11):1031-1039. doi:10.1056/NEJMsa1409364 read 9 October 2026. doi.org/10.1056/NEJMsa1409364
  15. Sheetz N, Wilson B, Benedict J, Huffman E, Lawton A, Travers M, et al. Evaluating source data verification as a quality control measure in clinical trials. Therapeutic Innovation & Regulatory Science. 2014;48(6):671-680. read 9 October 2026. journals.sagepub.com
  16. European Parliament and Council of the European Union. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Official Journal of the European Union (CELEX 32014R0536). 2014. read 9 October 2026. eur-lex.europa.eu
  17. Tudur Smith C, Williamson P, Jones A, Smyth A, Hewer SL, Gamble C. Risk-proportionate clinical trial monitoring: an example approach from a non-commercial trials unit. Trials. 2014;15:1-10. read 9 October 2026. journals.sagepub.com
  18. Macefield RC, Beswick AD, Blazeby JM, Lane JA. A systematic review of on-site monitoring methods for health-care randomised controlled trials. Clinical Trials. 2013;10(1):104-124. read 9 October 2026. journals.sagepub.com
  19. Kirkwood AA, Cox T, Hackshaw A. Application of methods for central statistical monitoring in clinical trials. Clinical Trials. 2013;10(5):783-806. read 9 October 2026. journals.sagepub.com
  20. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WSM, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Annals of Internal Medicine. 2013;158(3):200-207. doi:10.7326/0003-4819-158-3-201302050-00583 read 9 October 2026. doi.org/10.7326/0003-4819-158-3-201302050-00583
  21. Tudur Smith C, Stocken DD, Dunn J, Cox T, Ghaneh P, Cunningham D, Neoptolemos JP. The value of source data verification in a cancer clinical trial. PLoS ONE. 2012;7(12):e51623. read 9 October 2026. journals.sagepub.com
  22. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology. 2011;64(12):1283-1293. doi:10.1016/j.jclinepi.2011.01.012 read 9 October 2026. doi.org/10.1016/j.jclinepi.2011.01.012
  23. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology. 2011;64(4):383-394. doi:10.1016/j.jclinepi.2010.04.026 read 9 October 2026. doi.org/10.1016/j.jclinepi.2010.04.026
  24. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology. 2011;64(4):401-406. doi:10.1016/j.jclinepi.2010.07.015 read 9 October 2026. doi.org/10.1016/j.jclinepi.2010.07.015
  25. Journot V, Pignon JP, Gaultier C, Daurat V, Bouxin-Metro A, Giraudeau B, et al. Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies - the Pre-Optimon study. Contemporary Clinical Trials. 2011;32:16-24. read 9 October 2026. journals.sagepub.com
  26. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11(1):32. doi:10.1186/1745-6215-11-32 read 9 October 2026. doi.org/10.1186/1745-6215-11-32
  27. Brosteanu O, Houben P, Ihrig K, Ohmann C, Paulus U, Pfistner B, et al. Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials. Clinical Trials. 2009;6(6):585-596. read 9 October 2026. journals.sagepub.com
  28. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-926. read 9 October 2026. cobe.paginas.ufsc.br
  29. Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106-1110. read 9 October 2026. cobe.paginas.ufsc.br
  30. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336:995-998. read 9 October 2026. cobe.paginas.ufsc.br
  31. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD read 9 October 2026. doi.org/10.1136/bmj.39335.541782.AD
  32. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18(6):800-804. doi:10.1097/EDE.0b013e3181577654 read 9 October 2026. doi.org/10.1097/EDE.0b013e3181577654
  33. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294(2):218-228. doi:10.1001/jama.294.2.218 read 9 October 2026. doi.org/10.1001/jama.294.2.218
  34. Lawlor DA, Davey Smith G, Ebrahim S. Commentary: the hormone replacement-coronary heart disease conundrum: is this the death of observational epidemiology? International Journal of Epidemiology. 2004;33(3):464-467. doi:10.1093/ije/dyh124 read 9 October 2026. doi.org/10.1093/ije/dyh124

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 9). Mandatory Publication and Registration of Clinical Trials. Pubrica. https://pubrica.com/academy/case-reporting/publications-of-clinical-trials-in-scientific-journals-mandatory/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Registration and reporting control sheet

This should be consulted at protocol approval, not at submission. Three of the rows below record dates that become unchangeable public facts, and one of them, registration before first consent, cannot be remedied at all.

TRIAL REGISTRATION AND RESULTS REPORTING CONTROL SHEET

Trial short title: ______________________________________
Sponsor: ______________________  Sponsor type: ___________
Protocol version and date: ______________________________

PART A - PROSPECTIVE REGISTRATION (deadline: first consent)
  Registry chosen: ______________________
  [ ] Confirmed to be a WHO ICTRP primary register
  Registration record created, date: ______________
  Record live and public, date: ______________
  Date of first participant consent: ______________
  [ ] Registration date is BEFORE first consent date
      If not, record the reason for disclosure in the manuscript:
      ..........................................................

  Minimum data set (24 items) - the ones that cause trouble later:
  Primary outcome, stated to this precision:
    Construct: ______________________
    Instrument / measurement method: ______________________
    Timepoint: ______________________
    Metric (change from baseline, final value, time to event):
      ______________________
  [ ] Primary outcome wording matches the protocol word for word
  [ ] Secondary outcomes listed, not summarised
  [ ] Data-sharing plan entered in the registration record
      (required in the record since 2019)

PART B - STATUTORY RESULTS REPORTING (deadline: from completion)
  Jurisdiction(s) whose requirements apply: ________________
  Applicability determination:  [ ] applicable  [ ] not applicable
  Reasoning (do not leave this blank - 45% of industry trials
  assessed as likely applicable were not actually required):
    ..........................................................
  Determination made by: ______________  Date: ____________
  Review date if the trial or product status changes: _______

  Primary completion date (actual or anticipated): __________
  Results submission deadline: ______________
  Calendar owner (a named ROLE, not the trial): ______________
  [ ] Deadline entered in that person's calendar
  Results submitted, date: ______________
  [ ] Submitted without waiting for the manuscript

PART C - AMENDMENT LOG (registry must be updated each time)
  Date | What changed | Registry updated on | Affects primary?
  ---- | ------------ | ------------------- | ----------------
  .... | ............ | ................... | ................

PART D - MANUSCRIPT STATEMENT CHECK (before submission)
  [ ] Registration number given
  [ ] Registration date given
  [ ] Date of first consent given
  [ ] Registered primary outcome shown to be the reported one
  [ ] Registry amendment history disclosed with dates
  [ ] Date of statutory results submission given
  [ ] Data-sharing statement present and specific
      (repository, availability date, access conditions)
  [ ] Protocol supplied as a supplementary file, with its date
  [ ] Analysis plan supplied as a supplementary file, with its date

SENTENCES TO DELETE IF PRESENT
  [ ] "The trial was registered" with no date
  [ ] "Data are available on reasonable request" as the whole plan
  [ ] Any primary outcome in the paper that is not the registered one

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica builds the registry record from the protocol rather than the reverse, so that the registered primary outcome matches the protocol in instrument, timepoint and metric and the risk of inadvertent outcome switching is reduced. Pubrica records the applicability determination in writing with its reasoning, assigns the statutory reporting deadline to a named role, and drafts the registration and data-sharing statement of the manuscript so that an editor can verify each claim against public records. Where a trial was registered late, Pubrica assists with appropriate disclosure, which places the authors in a materially better position than discovery by a reviewer.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Comparison of the protocol and registry entry for discrepancies

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.